Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Glenmark Pharmaceuticals's Total Operating Expense for the
three
months ended in Mar. 2026 was ₹19,733 Mil. Glenmark Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹79,650 Mil.
Glenmark Pharmaceuticals Total Operating Expense Related Terms
Glenmark Pharmaceuticals Total Operating Expense Historical Data
* Premium members only.
The historical data trend for Glenmark Pharmaceuticals's Total Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glenmark Pharmaceuticals Total Operating Expense Chart
Glenmark Pharmaceuticals Total Operating Expense Calculation
Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.
Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹79,650 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Operating Expense of ₹79,650 Mil mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Total Operating Expense of ₹79,650 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Glenmark Pharmaceuticals and its competitors.
Is Glenmark Pharmaceuticals' Total Operating Expense too high?
Glenmark Pharmaceuticals' current Total Operating Expense is ₹79,650 Mil. Overall, Glenmark Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Total Operating Expense compare to ZTS and UTHR?
Glenmark Pharmaceuticals' Total Operating Expense of ₹79,650 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Glenmark Pharmaceuticals and its competitors. Glenmark Pharmaceuticals's current Total Operating Expense is ₹79,650 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,985.29, compared to a current price of ₹2,205.10 — trading 11.1% above its estimated fair value. The current Total Operating Expense is ₹79,650 Mil. Glenmark Pharmaceuticals' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Total Operating Expense is ₹79,650 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,205.10 is trading 11.1% above its estimated GF Value™ of ₹1,985.29.
GuruFocus considers Glenmark Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for NSE:GLENMARK:
Total Operating Expense: ₹79,650 Mil
GF Value™: ₹1,985.29 vs. price of ₹2,205.10 (11.1% above fair value)
No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
88GF Score
Get the complete analysis for NSE:GLENMARK
Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLENMARK has been successfully added to your 
